Portfolio

A portfolio of diagnostic tests combining speed and accuracy

Our Click chemistry-based portfolio focuses on the diagnosis of Legionnaires’ Disease (C4Legio LFA), urinary tract infections (C4UTI) and the development of antimicrobial susceptibility tests (C4AST). We have also developed a rapid saliva-based test for COVID-19 diagnosis (C4Covid-19 Human), CE marked since March 2021 and commercialized.

As Click-chemistry technology is robust and versatile, we intend to develop a full AST product line and address other therapeutic areas targeting other micro-organisms.

Our tests not only share the Click-chemistry technology, but they also aim to reconcile speed & accuracy. This double feature is our signature and brings leverage to fight antimicrobial resistance, which is one the biggest challenge humanity faces.